How to Get Evenity (Romosozumab) in Maryland

What Is Romosozumab and Why Does It Require Special Access?

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, romosozumab simultaneously stimulates new bone formation and reduces bone resorption, a dual mechanism unique among osteoporosis therapies 1. The FDA approved Evenity in April 2019 for postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors, or failure of other treatments 2.

Because of its cardiovascular black box warning and high cost, payers in Maryland require prior authorization before dispensing. This creates a multi-step access pathway that involves clinical documentation, lab verification, and specialty pharmacy coordination. The process is navigable with the right preparation. Below is a step-by-step breakdown for Maryland patients and their providers 3.

Step 1: Find a Qualified Prescriber in Maryland

Any licensed physician (MD or DO), nurse practitioner, or physician assistant in Maryland can prescribe Evenity, provided they hold an active Maryland license with prescriptive authority 4. NPs in Maryland have full practice authority after completing a supervised transition period per COMAR 10.27.01. PAs prescribe under a delegation agreement with a supervising physician.

Endocrinologists and rheumatologists are the most common prescribers of romosozumab, though primary care physicians with bone health expertise also initiate therapy. Telehealth consultations are fully legal for this purpose under Maryland Health-General Article §19-319, which permits synchronous audio-video encounters for prescribing controlled and non-controlled medications 5. HealthRX connects Maryland patients to board-certified clinicians experienced in anabolic bone therapy who can evaluate candidacy, order labs, and initiate the PA process remotely.

Step 2: Required Labs Before Prescribing

Before writing the prescription, your clinician will order baseline labs to confirm eligibility and rule out contraindications. The Endocrine Society's 2020 clinical practice guideline recommends the following panel prior to anabolic therapy 6:

• DXA scan: T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip (or -1.0 to -2.5 with FRAX-calculated 10-year major osteoporotic fracture probability of 20% or greater)
• Serum calcium: must be within normal limits (8.5 to 10.5 mg/dL); hypocalcemia is a contraindication
• 25-hydroxyvitamin D: levels should exceed 20 ng/mL (preferably above 30 ng/mL) before initiation
• Comprehensive metabolic panel: assesses renal function and electrolytes
• PTH (parathyroid hormone): to exclude hyperparathyroidism
• CTX or P1NP: bone turnover markers for baseline comparison

The FDA label specifically warns against initiating romosozumab in patients with hypocalcemia. Correct calcium and vitamin D deficiency before the first dose 2. A cardiovascular risk assessment is also mandatory given the ARCH trial finding of higher cardiovascular event rates in the romosozumab group during the first 12 months (2.5% vs. 1.9% for alendronate) 1.

Step 3: Prior Authorization in Maryland

Both Maryland Medicaid and most commercial insurers (CareFirst BlueCross BlueShield, Aetna, UnitedHealthcare) require prior authorization for Evenity. The typical documentation package includes 7:

• DXA report showing qualifying T-score
• Documentation of prior fracture or FRAX score
• Lab results confirming normal calcium
• Cardiovascular risk statement (no MI or stroke in prior 12 months)
• Failure of or contraindication to at least one antiresorptive agent (bisphosphonate or denosumab)

Maryland Medicaid follows CMS guidelines and covers Evenity for severe osteoporosis when the patient meets step-therapy requirements. The AACE 2020 guidelines classify romosozumab as first-line for "very high fracture risk" patients, defined as those with recent fracture (within 12 months), fractures while on approved therapy, or T-score below -3.0 8.

Turnaround for PA decisions in Maryland is typically 3 to 7 business days. If denied, your provider can file a peer-to-peer review. Maryland Insurance Administration regulations require insurers to complete urgent PAs within 24 hours.

Step 4: Specialty Pharmacy and 503A Options

Once approved, the prescription routes to a specialty pharmacy. Amgen's Evenity Together program facilitates access through preferred specialty pharmacies like Optum Specialty, Accredo, and CVS Specialty 9. These pharmacies ship directly to the patient's home or to the administering provider's office.

Maryland also licenses 503A compounding pharmacies under COMAR 10.34.19, which can prepare sclerostin inhibitor formulations when a patient-specific prescription exists. This route may offer cost savings for uninsured patients, though biosimilar compounding of monoclonal antibodies faces complex regulatory considerations under FDA guidance 10.

Standard dispensing: the pharmacy ships two 105 mg/1.17 mL prefilled syringes per monthly dose (total 210 mg given as two subcutaneous injections in the same visit). Cold chain shipping maintains the product at 2 to 8 degrees Celsius 2.

Clinical Evidence Supporting Romosozumab Use

The ARCH trial (N=4,093) compared romosozumab followed by alendronate versus alendronate alone over 24 months. Romosozumab reduced new vertebral fractures by 48% (4.0% vs. 7.7%, P<0.001) and clinical fractures by 27% 1. The FRAME trial (N=7,180) showed romosozumab reduced vertebral fractures by 73% versus placebo at 12 months (0.5% vs. 1.8%, P<0.001) 3.

Bone mineral density gains are substantial. In FRAME, lumbar spine BMD increased 13.3% at 12 months with romosozumab, compared to 0.0% with placebo 3. The STRUCTURE trial demonstrated that romosozumab increased total hip BMD by 2.9% at 12 months versus a 0.5% loss with teriparatide in patients transitioning from bisphosphonates 11.

These data support the Endocrine Society's positioning of romosozumab as an appropriate first-line anabolic agent for patients at very high fracture risk who need rapid BMD gains 6.

Cardiovascular Safety Considerations for Maryland Patients

The FDA's black box warning stems from the ARCH trial observation of a numerical imbalance in major adverse cardiovascular events (MACE): 50 events in the romosozumab group vs. 38 with alendronate during the 12-month open-label period 1. A 2023 meta-analysis pooling ARCH, FRAME, and BRIDGE data (N=11,990 combined) found no statistically significant increase in MACE with romosozumab versus placebo (OR 1.18 to 95% CI 0.77 to 1.81), though the confidence interval does not exclude risk 12.

Maryland providers must document cardiovascular history before prescribing. Absolute contraindications include myocardial infarction or stroke within the preceding 12 months. The prescribing information advises discontinuation if a cardiovascular event occurs during treatment 2. Patients with established atherosclerotic disease warrant individualized risk-benefit discussion with cardiology input.

What to Expect During the 12-Month Treatment Course

Each monthly visit involves two subcutaneous injections administered sequentially in the abdomen, thigh, or upper arm. The visits take approximately 15 to 20 minutes including post-injection observation. Most patients tolerate injections well; the FRAME trial reported injection-site reactions in 5.2% of romosozumab patients versus 2.9% placebo 3.

After completing 12 monthly doses, patients transition to an antiresorptive agent (typically alendronate or denosumab) to maintain BMD gains. The ARCH trial protocol transitioned patients to alendronate 70 mg weekly, and BMD continued to increase through month 24 1. Without sequential antiresorptive therapy, BMD gains from romosozumab reverse within 12 months, similar to teriparatide discontinuation patterns 13.

Repeat DXA scanning is typically performed at month 12 (end of romosozumab course) and again at month 24. Bone turnover markers (P1NP and CTX) may be checked at 1, 3, and 6 months to confirm pharmacologic response 6.

Cost and Financial Assistance in Maryland

Evenity's wholesale acquisition cost is approximately $1,825 per monthly dose, totaling roughly $21,900 for the full 12-dose course. Commercial copay assistance through Amgen's Evenity Together program can reduce out-of-pocket costs to as low as $5 per month for eligible patients with commercial insurance 14.

Maryland Medicaid covers Evenity with PA approval, and patients have zero cost-sharing. Medicare Part B covers Evenity as a physician-administered injectable under the medical benefit, with standard 20% coinsurance after deductible. The Medicare Savings Program can assist low-income Maryland beneficiaries with cost-sharing 15.

For uninsured Maryland residents, Amgen's patient assistance program provides Evenity at no cost to qualifying individuals with household income below 300% of the federal poverty level. Application requires income documentation and a signed prescription.

Telehealth Access Pathways in Maryland

Maryland's telehealth parity law (Health-General §19-319) requires commercial insurers to cover telehealth visits at the same rate as in-person visits. This means the initial consultation, lab review, and PA submission can all occur remotely 5. The physical injections still require in-person administration, either at a local clinic, infusion center, or through home health nursing.

The typical telehealth workflow for Evenity in Maryland:

1. Virtual consultation (Day 1): History review, fracture risk assessment, cardiovascular screening
2. Lab orders (Days 1 to 7): Sent electronically to Quest, LabCorp, or a local Maryland draw site
3. Results review (Days 7 to 10): Second telehealth visit to discuss results, confirm eligibility
4. PA submission (Days 10 to 14): Provider submits to insurer with supporting documentation
5. PA decision (Days 14 to 21): Approval or peer-to-peer review
6. First injection (Days 21 to 28): Scheduled at nearest administering provider

Total time from first consultation to first injection averages 3 to 4 weeks, though urgent cases with recent fracture may qualify for expedited PA review under Maryland's 24-hour urgent authorization rule 16.

Transferring a Romosozumab Prescription to Maryland

Patients relocating to Maryland mid-treatment can transfer their Evenity prescription. Maryland Board of Pharmacy regulations permit out-of-state prescription transfers for specialty medications. The receiving specialty pharmacy verifies the original PA, and if the patient's insurer operates in Maryland, the existing authorization typically carries over. If switching insurers, a new PA may be required. Bring your most recent DXA report, lab results, and injection log to avoid redundant testing 6.

For patients transferring from a Medicare Advantage plan in another state to Maryland FFS Medicare, the Part B medical benefit covers Evenity nationally without geographic restriction.